These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24358154)

  • 1. Translational science by public biotechnology companies in the IPO "class of 2000": the impact of technological maturity.
    McNamee L; Ledley F
    PLoS One; 2013; 8(12):e82195. PubMed ID: 24358154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late-stage Product Development and Approvals by Biotechnology Companies After Initial Public Offering, 1997-2016.
    McNamee LM; Cleary EG; Zhang S; Salim U; Ledley FD
    Clin Ther; 2021 Jan; 43(1):156-171.e15. PubMed ID: 33380363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustainability reporting and corporate reputation of Malaysian IPO companies.
    Abbas YA; Mehmood W; Lazim YY; Aman-Ullah A
    Environ Sci Pollut Res Int; 2022 Nov; 29(52):78726-78738. PubMed ID: 35697988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Business Models in Funding the Biotech Industry: Global Trends and Challenges for Cuban Biotechnology.
    Blanco-García E
    MEDICC Rev; 2020 Jan; 22(1):11-16. PubMed ID: 32327617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Australia's bio-regulatory framework: leading the way for stem cell research.
    Hill H
    J Biolaw Bus; 2004; 7(2):61-4. PubMed ID: 15460561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
    Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB
    Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond and between academia and business: How Austrian biotechnology researchers describe high-tech startup companies as spaces of knowledge production.
    Fochler M
    Soc Stud Sci; 2016 Apr; 46(2):259-81. PubMed ID: 27263239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Swiss Startup Framework: A Highly Effective Network Supporting the Generation of Emerging Biotech Businesses.
    Mitchell I; Steiner S; Altorfer M; Suter-Dick L
    Chimia (Aarau); 2020 Oct; 74(10):765-767. PubMed ID: 33115556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why commercialization of gene therapy stalled; examining the life cycles of gene therapy technologies.
    Ledley FD; McNamee LM; Uzdil V; Morgan IW
    Gene Ther; 2014 Feb; 21(2):188-94. PubMed ID: 24305420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Demonstrating the value of digital health: Guidance on contextual evidence gathering for companies in different stages of maturity.
    Halminen O; Chen A; Tenhunen H; Lillrank P
    Health Serv Manage Res; 2021 Feb; 34(1):13-20. PubMed ID: 33291977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The changing environment for technological innovation in health care.
    Goodman CS; Gelijns AC
    Baxter Health Policy Rev; 1996; 2():267-315. PubMed ID: 11066263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Market entry and exit by biotech and device companies funded by venture capital.
    Burns LR; Housman MG; Robinson CA
    Health Aff (Millwood); 2009; 28(1):w76-86. PubMed ID: 19049998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Danger in the Valley of Death: how the transition from preclinical research to clinical trials can impact valuations.
    Truebel H; Thurston T
    Drug Discov Today; 2020 Dec; 25(12):2089-2094. PubMed ID: 33031944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Related to Small- and Mid-Capitalization Pharmaceutical Company Success Using Stock Performance as a Surrogate.
    Ferris MJ; Sun K; Savard C; Suresh T; Mishra MV
    Cureus; 2021 Sep; 13(9):e18210. PubMed ID: 34692353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Historical sketch of modern pharmaceutical science and technology (Part 4). Post World War II 50 years].
    Yamakawa K
    Yakushigaku Zasshi; 1995; 30(2):75-90. PubMed ID: 11613536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A venture capital view of challenges, opportunities, and innovation in biomedical research.
    Ratcliffe LT
    Clin Pharmacol Ther; 2011 Feb; 89(2):174-6. PubMed ID: 21252935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. H2020 EU Research & Innovation Program Boost the Transfer of Technological Breakthroughs, Enable New Solutions for Personalised Health and Impact the Industry and Healthcare Systems.
    Smit PH; Lymberis A
    Stud Health Technol Inform; 2015; 211():3-17. PubMed ID: 25980846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing long-term value creation after biotech and non-biotech IPOs, 1997-2016.
    Cleary EG; McNamee LM; de Boer S; Holden J; Fitzgerald L; Ledley FD
    PLoS One; 2021; 16(1):e0243813. PubMed ID: 33406113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wall Street's assessment of plastic surgery--related technology: a clinical and financial analysis.
    Krieger LM; Shaw WW
    Plast Reconstr Surg; 2000 Feb; 105(2):609-16. PubMed ID: 10697168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Value of Scientific Publications in Surgical Device Innovation.
    Song A; Rensi SE; Tarquinio AG; Cahan E; de Ruijter VE; Wall JK
    Surg Innov; 2023 Oct; 30(5):615-621. PubMed ID: 36511818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.